Share this Page:
In a recent analysis of a large database, researchers compared baseline clinical/pathological characteristics and survival outcomes of localised type 1 papillary renal cell carcinoma (pRCC) and type 2 pRCC patients.
This study, the largest study of localised pRCC published to date, showed that type 2 pRCC patients were more likely to be diagnosed with higher tumour stage, higher grade, and larger tumours. In addition, type 2 pRCC patients had higher rates of all-cause mortality and shorter progression-free survival.
In conclusion, this study provides real-world evidence confirming that type 2 pRCC patients have worse prognosis compared with type 1 pRCC patients.